MedTrace Logo

Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

NCT05684380 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 514

Last updated 2024-02-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of MAZ-101 in the treatment of moderate-severe persistent allergic rhinitis.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

MAZ-101association

Experimental drug

DRUG

DYMISTA®

Active comparator

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2024-11-30
Completion
2025-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05684380 on ClinicalTrials.gov